We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Celgene Continues Active January With $9B Juno Acquisition

Law360, New York (January 22, 2018, 8:49 AM EST) -- Celgene has agreed to buy rival biotechnology business Juno Therapeutics for around $9 billion, the companies said Monday, marking the second multibillion-dollar acquisition made by Celgene this month.

Under the terms of the transaction, Summit, New Jersey-based Celgene Corp. will acquire Seattle-headquartered Juno Therapeutics Inc. for $87 per share in cash. The deal, which was rumored last week, has been approved by the boards of directors for both companies.

Juno is focused on developing immunotherapies to treat cancer. The company has several product candidates that it...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.